Patent ID: 6290956
Filing Date: 2001-09-18
Classification: A61K,A61P,C07K,G01N,Y10S

Abstract:
A method of ablating or killing normal, benign hyperplastic prostate epithelial cells or cancerous prostate epithelial cells in a patient comprising administering:(a) an isolated antibody or antigen binding portion thereof which binds to the extracellular domain of prostate specific membrane antigen (PSMA) which binding occurs on living cells;contacting said cells with the isolated antibody or antigen binding portion thereof under conditions effective to permit binding of the isolated antibody or antigen binding portion thereof to the extracellular domain of the PSMA wherein immune effector cells and/or complement components are recruited to the antibody/cell complex, thereby ablating or killing said cells and administering;(b) a second isolated antibody or antigen binding portion thereof which binds to the extracellular domain of PSMA; contacting said cells with the second isolated antibody or antigen binding portion thereof under conditions effective to permit binding of the second isolated antibody or antigen binding portion to the extracellular domain of the PSMA wherein immune effector cells and/or complement components are recruited to the antibody/cell complex, thereby ablating or killing said cells.